Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular Ca
-
Cyabra to Present at the ThinkEquity Conference in New York City on October 30
-
Pyxis Tankers to Present at the 2024 ThinkEquity Conference
-
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis
-
Orgenesis Commences Trading on OTCQX® Best Market
-
FREEBIRDS CELEBRATES SECOND ANNUAL NATIONAL FREEBIRDS DAY ON OCTOBER 28TH
-
Taseko Mines Provides Construction Update for Florence Copper
-
Life Biosciences Presents at AAO Highlighting Progress of Nonhuman Primate Studies Evaluating Partial Epigenetic Reprogramming to Restore Visual Function
-
First Onsite expands its presence in New England with key hirings
-
COUR Pharmaceuticals Announces Late-Breaking Poster for Phase 2a Data of CNP-104 in Primary Biliary Cholangitis Accepted for Presentation at The Liver Meeting® 2024
-
Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D.
-
Ekso Bionics to Report Third Quarter 2024 Financial Results on October 28, 2024
-
Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support
-
Windtree To Present at the ThinkEquity Conference on October 30th
-
ManTech Opens Center for Innovation and Partnership in Hawaii to Support Department of Defense Missions in the Indo-Pacific
-
VERSES and Volvo Cars Demonstrate Pedestrian Vehicle Safety Advancement
-
SERB Pharmaceuticals expands leading emergency care portfolio with acquisition of Aurlumyn™ (iloprost IV) for severe frostbite
-
Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET
-
LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia
-
5E Advanced Materials Reports Steady State Operations and Obtains Tax Exclusion For Lithium Capex
-
Music Licensing, Inc. (OTC: SONG) Retains SmallCapVoice.com Inc. (“SCV”) to Provide Investor Relations Services
-
Dayforce Launches New Brand Campaign: ‘Do the Work You’re Meant to Do’
-
James Richberg Appointed to Mattermost Federal Board of Directors
-
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
-
Stingray Partners with Xperi to Introduce Eight New Video Channels on Leading Premium OEM’s In-Car Screens
-
BDev Ventures Announces Strategic Investment in Recyclops
-
STMicroelectronics Announces Status of Common Share Repurchase Program
-
Taboola Signs Exclusive Deal with National World and Axiom Media Alliance (AMA) to Power Content Recommendations Across the National World Network of Regional Sites Including Yorkshire Evening Post an
-
Office Depot and Telos Corporation Surpass 160 TSA PreCheck® Enrollment Locations Nationwide
-
Neuroscience for Crisis Negotiators at S.W.A.T. Conference
-
Renegade IDO to Debut on DeFi.Gold Launchpad, Bridging TradFi with Crypto
-
Karolinska Development’s portfolio company SVF Vaccines announces positive data from a phase 1 study of its universal Covid-19 vaccine
-
FishWar Officially Powered by Sei: Elevating the GameFi Experience
-
Aveanna to Participate Virtually at the Stephens Annual Investment Conference
-
Pasinex Announces Entry into Option and Purchase Agreement
-
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
-
Volcon CEO John Kim provides a UTV product roadmap update
-
NanoXplore to Host a Webcast to Discuss First Quarter Results on November 7th, 2024
-
SL Green Realty Corp. Announces Common Stock Dividend
-
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
-
Probe Gold Files NI 43-101 Technical Reports for Novador Project, McKenzie Break Property and Croinor Gold Property
-
Finch Announces Delisting from Nasdaq and SEC Deregistration
-
NORBIT - New Registered Share Capital
-
IBN Initiates Coverage of Brera Holdings PLC
-
CoinW Launches the CoinW Legend Cup (CWLC) with a $1 Million Prize Pool, Featuring a Tesla Cybertruck, and More
-
Bombardier’s Global 8000, the World’s Fastest Business Jet, Speeds Forward as Manufacturing Begins
-
KFSHRC Successfully Conducts Pharmacogenetic Analysis for Over 1,500 Patients
-
Little Tikes® Story Dream Machine™ Launches All-New Story Collections for the Fall and Holidays in Partnership with Paramount®, DreamWorks Animation, The Pinkfong Company, and The Jim Henson Compa
-
Onity Group Announces Proposed Offering of $475 Million of Senior Notes Due 2029
-
HBT Financial, Inc. Announces Third Quarter 2024 Financial Results
